Abstract:Objective:To investigate the clinical significance of accessory hepatic vein (AHV) pressure reduction in treatment of Budd-Chiari syndrome (BCS). <br> Methods:The clinical data of 27 BCS patients treated during March 2007 to July 2015 were retrospectively analyzed. Of the patients, 11 cases were male and 16 cases were female, with an average of (46±8) years old;9 cases had lesions in the opening of AHV, 12 cases had occlusion in the inferior vena cava (IVC) and 6 cases had mixed lesions of AHV and IVC. <br> Results:All patients underwent venography and manometry of the AHV and endovascular treatment. Ninepatients with AHV disease underwent balloon dilatation angioplasty of the AHV, and their preoperative AHV pressure dropped from (25±4) cmH2O to (17±3) cmH2O;in the 12 patients with IVC disease, 10 cases underwent balloon dilatation angioplasty of the IVC and 2 cases underwent open surgery, and the preoperative AHV and intrahepatic IVC pressure decreased from (27±6) cmH2O to (15±4) cmH2O and from (27±5) cmH2O to (14±3) cmH2O, respectively;in the 6 cases with both AHV and IVC involvements, the preoperative pressure of AHV and IVC declined from (28±6) cmH2O to (14±4) cmH2O and from (26±5) cmH2O to (13±4) cmH2O, respectively. The abdominal symptoms were significantly relieved 3 days after operation in all patients and the edema in lower limbs was remarkably alleviated in those with IVC lesion, with treatment effective rate of 100%. No complications such as bleeding and pulmonary embolism occurred. Twenty-three patients were followed up for 4 to54 months, doppler ultrasound at 6 months atfer operation showed that the patency rate of original lesion was 100%and, at a later time, IVC re-occlusion occurred in 2 cases which were resolved by second balloon dilatation. <br> Conclusion:AHV pressure reduction can help to alleviate the symptoms of BCS patients, and attention should be paid to the existence of the AHV and the treatment of its problems.

Efficacy of Warfarin for Budd-Chiari Syndrome Associated with Inferior Vena Cava Thrombosis

Anticoagulation with warfarin for Budd-Chiari syndrome with chronic inferior vena cava thrombosis: an initial clinical experience.

Clinical study of cerebral infarction prevention with warfarin in nonvalvular atrial fibrillation

Staged Management of Budd-Chiari Syndrome Caused by Co-Obstruction of the Inferior Vena Cava and Main Hepatic Veins.

Randomized Study of Efficiency and Safety of Antithrombotic Therapy with Warfarin in Nonvalvular Atrial Fibrillation

Endovascular treatment of Budd-Chiari syndrome with occlusion of hepatic veins

Anticoagulation Par La Warfarine Pour Syndrome De Budd–Chiari Avec Thrombose Chronique De La Veine Cave Inférieure : Expérience Clinique Initiale

Interventional Treatment of Budd-Chiari Syndrome:Report of 312 Cases

INTERVENTIONAL OR SEMI-INTERVENTIONAL TREATMENT FOR BUDD-CHIARI SYNDROME

Significance of accessory hepatic vein pressure reduction in treatment of Budd-Chiari syndrome

The diagnosis and treatment of Budd-Chiari syndrome with inferior vena cava thrombosis

Analysis of Surgical Treatment Results in 120 Cases of Budd-Chiari Syndrome

Interventional and Surgical Treatment of Budd-Chiari Syndrome: A Report of 39 Cases

Comparative effectiveness of warfarin in cirrhotic patients with non-symptomatic portal vein thrombosis: a multicenter, randomized controlled trial

Inferior Vena Cava Dilatation and Stent Implantation Combined with Splenorenal Shunt to Treat Budd-Chiari Syndrome

Comparison of the therapeutic effect between interventional treatment and anticoagulation therapy alone in patients with intracranial venous sinus thrombosis

Endovascular treatment of segmental occlusive Budd-Chiari syndrome

Modified Transjugular Intrahepatic Portosystemic Shunt In The Treatment Of Budd-Chiari Syndrome

Good Clinical Outcomes in Budd–Chiari Syndrome with Hepatic Vein Occlusion

Cavo-meso-atrial Shunt for the Treatment of Budd-Chiari Syndrome Due to Combined Occlusion of Inferior Vena Cava and Hepatic Vein